Actinium Announces Selection of Zevacor Pharma, Inc. for Clinical Production and Supply of Lomab-B for Pivotal Phase 3 SIERRA Trial Apr 12, 2016
Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B Apr 6, 2016
Actinium Further Strengthens Clinical Development Team With Hiring of Director of Clinical Operations Mar 31, 2016
Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients Mar 30, 2016
Actinium Pharmaceuticals to Present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference Mar 11, 2016
Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B Mar 8, 2016
